Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

NCT04741165 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: HX008
DRUG: Bevacizumab
DRUG: Lenvatinib

Sponsor

Taizhou Hanzhong biomedical co. LTD